Trial of NovoSorb hit with delays: Calzada
24 August, 2012 by Dylan Bushell-EmblingCalzada (ASX:CZD) has been forced to push back the planned completion date for a planned human clinical trial of its NovoSorb BTM burns treatment product until well into 2013.
Court calls meeting to vote on Alchemia spinoff
24 August, 2012 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has reached two new milestones in its efforts to spin off its oncology business into a separate company listed on the Nasdaq.
Patrys raises cash, shaves loss in FY12
23 August, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) ended FY12 in a more stable financial position, after raising enough cash to see it through until early 2014.
Business Tax Working Group discusses cuts to R&D Tax Incentive
23 August, 2012 by AusBiotechAusBiotech invites members’ comments on the recently released Business Tax Working Group (BTWG) discussion paper, which includes amongst its issues for discussion four options that seek to limit the R&D Tax Incentive to companies with turnover over $20 million.
GI Dynamics gets FDA provisional nod for pivotal EndoBarrier trial
23 August, 2012 by Dylan Bushell-EmblingThe US FDA has provisionally cleared GI Dynamics (ASX:GID) to jump straight to a full clinical trial of EndoBarrier to treat Type 2 diabetes patients who are obese.
Mesoblast stem cell R&D spend triples
22 August, 2012 by Tim DeanMesoblast (ASX:MSB) has reinvested a sizeable chunk of the revenues from its licensing deal with Cephalon into boosting research and development efforts for its adult stem cell technology, bumping up total expenses by more than $58 million in FY12.
Oncology start-up Senz gets seed funding for chemo agent
22 August, 2012 by Dylan Bushell-EmblingStart-up Senz Oncology has secured seed funding to support the development of a chemotherapeutic agent as a potential treatment for acute leukaemias.
CSL lifts FY12 profit to US$1 billion
22 August, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) grew its FY12 net profit 4.5% to $983 million, despite taking a significant hit on exchange rates.
BioDiem viral vector research clears first hurdle
21 August, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and French partner VIVALIS have reached two significant milestones in their work towards the development of a new viral vector.
PM’s Manufacturing Taskforce reports
21 August, 2012 by AusBiotechNon-government members of the Prime Minister's Manufacturing Taskforce, representing business, unions and the research sector, have released their report Smarter Manufacturing for a Smarter Australia, after the group was established in late 2011.
Bioniche launching more animal health products
21 August, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) has launched an equine inflammation treatment in the US, and scored Canadian distribution rights for six more products.
QRxPharma meets with FDA about MoxDuo IR knockback
20 August, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) executives left a pivotal meeting with the US FDA hopeful of being able to avoid prolonging the MoxDuo IR approvals process with another clinical trial.
Manufacturing Taskforce largely overlooks biotechnology
17 August, 2012 by Tim DeanThe Prime Minister’s Manufacturing Taskforce report from non-government members, released yesterday, has focused largely on traditional manufacturing with little attention given to the biotechnology, pharmaceutical and medical device manufacturing sectors.
AusBiotech national office on the move…
16 August, 2012 by AusBiotechThe national office of AusBiotech will move this weekend from its current location in Malvern to Level 4, 627 Chapel Street, South Yarra Victoria.
Opinion: Scrapping the R&D tax incentive is hardly a smart idea for economic policy
16 August, 2012 by Staff WritersThe Business Tax Working Group discussion paper’s suggestion to reduce the R&D tax incentive reveals a clear-cut attitude to policy aimed at Australia’s economic development: “It’s all about the tax take.”
